U.S. taps U.K. firm for bio-defense work

Jan. 16, 2013 at 2:40 PM

OXFORD, England, Jan. 16 (UPI) -- Pharmacological agents that improve the efficacy of bio-defense vaccines are to be developed by a British company under a contract from the U.S. military.

PsiOxus Therapeutics Ltd. , a development stage bio-technology company, said the contract was issued by the U.S. Defense Threat Reduction Agency, is worth $3.3 million and is for a period of three years.

The company said it will use its proprietary PolyMAP technology – a immunotherapeutic platform combining polymers and synthetic adjuvants – to help improve the safety and efficacy of two vaccines candidates, the recombinant Protective Antigen for Anthrax and the Venezuelan Equine Encephalopathy Virus.

"We are honored to have received this contract from the DTRA and excited at the prospect of helping to improve the safety and efficacy of these two very important vaccine candidates using the PolyMAP technology," said Dr. John Beadle, chief executive officer of PsiOxus Therapeutics.

"Adjuvant platforms are key to innovating and growing the global vaccine market, and we are confident that our immunotherapeutic platform PolyMAP, along with our oncolytic vaccines expertise and team of renowned scientists, will play a significant and long-term role in the future of the industry."

Like Us on Facebook for more stories from UPI.com  
Related UPI Stories
Latest Headlines
Top Stories
Ford recalls 432,000 North American vehicles over software bug
New Zealand military receives medium heavy military trucks
BBC to lay off 1,000 people to make up for $234M in lost revenue
U.S. proposes tighter pipeline spill rules
Aetna to acquire Humana for $37 billion in cash, stocks